GFR斜率作为肾衰竭替代终点的荟萃分析
该研究基于66项研究共186,312例参与者的个体数据,采用贝叶斯混合效应荟萃回归模型,评估治疗对总GFR斜率(基线至3年)和慢性斜率(随机化后3个月起)的效应与临床终点(血清肌酐加倍、GFR<15 ml min-1 per 1.73 m2或需要替代治疗的肾衰竭)效应之间的关联。结果显示,临床终点治疗效应与总斜率治疗效应强相关(R2中位数=0.97,95% BCI 0.82-1.00),与慢性斜率中度相关(R2=0.55,95% BCI 0.25-0.77),且无疾病间异质性证据。结果支持将总斜率作为CKD进展临床试验的主要终点。
要点
- 临床终点治疗效应与总GFR斜率治疗效应强相关,R2中位数=0.97(95% BCI 0.82-1.00)。
- 临床终点治疗效应与慢性GFR斜率治疗效应中度相关,R2=0.55(95% BCI 0.25-0.77)。
- 不同疾病组间无显著异质性,结果支持总斜率作为CKD进展试验主要终点。
核心结论
- 结果支持将总GFR斜率作为慢性肾脏病进展临床试验的主要终点。
研究设计与样本
- 对66项研究共186,312例参与者的个体参与者数据进行分析,采用贝叶斯混合效应荟萃回归模型评估治疗效应。
主要发现
- 临床终点治疗效应与总斜率治疗效应强相关,R2中位数=0.97(95% BCI 0.82-1.00)。
- 临床终点治疗效应与慢性斜率治疗效应中度相关,R2=0.55(95% BCI 0.25-0.77)。
- 未发现疾病组间异质性证据。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a diverse spectrum of interventions and populations is required for acceptance of GFR decline as an endpoint. In an analysis of individual participant data, for each of 66 studies (total of 186,312 participants), we estimated treatment effects on the total GFR slope, computed from baseline to 3 years, and chronic slope, starting at 3 months after randomization, and on the clinical endpoint (doubling of serum creatinine, GFR < 15 ml min-1 per 1.73 m2 or kidney failure with replacement therapy). We used a Bayesian mixed-effects meta-regression model to relate treatment effects on GFR slope with those on the clinical endpoint across all studies and by disease groups (diabetes, glomerular diseases, CKD or cardiovascular diseases). Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median coefficient of determination (R2) = 0.97 (95% Bayesian credible interval (BCI) 0.82-1.00)) and moderately associated with those on chronic slope (R2 = 0.55 (95% BCI 0.25-0.77)). There was no evidence of heterogeneity across disease. Our results support the use of total slope as a primary endpoint for clinical trials of CKD progression.
引用
- Inker LA, Collier W, Greene T, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023. PMID: 37330614. doi:10.1038/s41591-023-02418-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。